Literature DB >> 16447821

Basic principles and applications of fractal geometry in pathology: a review.

Pranab Dey1.   

Abstract

The basic principles and prospects of fractal geometry in pathology are promising. All articles found with a PubMed search with the keywords fractal dimension (FD) and related to pathology were reviewed. All fractal objects have FDs, commonly calculated with box counting. Fractal geometry has been applied to measure the irregularities of nuclear and glandular margins to distinguish malignant lesions from benign ones, to measure the infiltrative margin of a malignant tumor, to assess tumor angiogenesis and to measure the distribution of collagen in tissue. Fractal geometry has also been applied to assess the irregular distribution of chromatin in malignant cells. Biologic model formation is possible with fractal geometry. In the future, fractal geometry may help with the diagnosis, understanding of pathogenesis and management of lesions. It may also provide new insights into disease processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16447821

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  14 in total

1.  Preclinical evaluation of nuclear morphometry and tissue topology for breast carcinoma detection and margin assessment.

Authors:  Ndeke Nyirenda; Daniel L Farkas; V Krishnan Ramanujan
Journal:  Breast Cancer Res Treat       Date:  2010-05-06       Impact factor: 4.872

Review 2.  Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue.

Authors:  Antonio Di Ieva; Fabio Grizzi; Paolo Gaetani; Umberto Goglia; Manfred Tschabitscher; Pietro Mortini; Riccardo Rodriguez y Baena
Journal:  Neurosurg Rev       Date:  2008-03-08       Impact factor: 3.042

3.  [Fractal geometry in the objective grading of prostate carcinoma].

Authors:  P Waliszewski; F Wagenlehner; S Gattenlöhner; W Weidner
Journal:  Urologe A       Date:  2014-08       Impact factor: 0.639

4.  (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

Authors:  C Sachpekidis; M Eder; K Kopka; W Mier; B A Hadaschik; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-12       Impact factor: 9.236

5.  68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Authors:  Christos Sachpekidis; P Bäumer; K Kopka; B A Hadaschik; M Hohenfellner; A Kopp-Schneider; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-23       Impact factor: 9.236

6.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

7.  The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.

Authors:  I Debergh; N Van Damme; P Pattyn; M Peeters; W P Ceelen
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

8.  Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?

Authors:  Ludwig G Strauss; Sven Klippel; Leyun Pan; Klaus Schönleben; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-12       Impact factor: 10.057

9.  Automated biochemical, morphological, and organizational assessment of precancerous changes from endogenous two-photon fluorescence images.

Authors:  Jonathan M Levitt; Margaret E McLaughlin-Drubin; Karl Münger; Irene Georgakoudi
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

10.  Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels.

Authors:  W Ceelen; T Boterberg; P Smeets; N Van Damme; P Demetter; O Zwaenepoel; L Cesteleyn; P Houtmeyers; M Peeters; P Pattyn
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.